- Home
- Publications
- Publication Search
- Publication Details
Title
Identification of NTRK
fusions in pediatric mesenchymal tumors
Authors
Keywords
-
Journal
PEDIATRIC BLOOD & CANCER
Volume 64, Issue 8, Pages e26433
Publisher
Wiley
Online
2017-01-18
DOI
10.1002/pbc.26433
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- NTRKfusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States
- (2016) Manju L. Prasad et al. CANCER
- MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research
- (2016) W. Chang et al. CLINICAL CANCER RESEARCH
- ALK,ROS1andNTRK3gene rearrangements in inflammatory myofibroblastic tumours
- (2016) Hidetaka Yamamoto et al. HISTOPATHOLOGY
- Infantile Fibrosarcoma WithNTRK3-ETV6Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101
- (2016) Ramamoorthy Nagasubramanian et al. PEDIATRIC BLOOD & CANCER
- Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors
- (2016) D. Williams Parsons et al. JAMA Oncology
- Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors
- (2016) Marian H. Harris et al. JAMA Oncology
- Mammary Analogue Secretory Carcinoma of Salivary Glands
- (2015) Yohei Ito et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Molecular Characterization of Inflammatory Myofibroblastic Tumors With Frequent ALK and ROS1 Gene Fusions and Rare Novel RET Rearrangement
- (2015) Cristina R. Antonescu et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth
- (2015) Rajen J. Mody et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib
- (2015) Victor Wong et al. JNCI-Journal of the National Cancer Institute
- Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
- (2015) Andrea Sartore-Bianchi et al. JNCI-Journal of the National Cancer Institute
- Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
- (2015) Anna F. Farago et al. Journal of Thoracic Oncology
- An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
- (2015) R. C. Doebele et al. Cancer Discovery
- Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib
- (2015) Victor Wong et al. JNCI-Journal of the National Cancer Institute
- Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
- (2015) Andrea Sartore-Bianchi et al. JNCI-Journal of the National Cancer Institute
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma
- (2014) Gang Wu et al. NATURE GENETICS
- Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions
- (2014) C. M. Lovly et al. Cancer Discovery
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
- Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
- (2013) Aria Vaishnavi et al. NATURE MEDICINE
- Congenital giant intramedullary spinal cord schwannoma
- (2010) C. A. Lyle et al. NEUROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started